List of Harvoni drug patents
Harvoni is owned by Gilead Sciences Inc.
Harvoni contains Ledipasvir; Sofosbuvir.
Harvoni has a total of 33 drug patents out of which 0 drug patents have expired.
Harvoni was authorised for market use on 10 October, 2014.
Harvoni is available in tablet;oral dosage forms.
Harvoni can be used as for the treatment of hepatitis c, for the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; for the treatment of hepatitis c; for treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks.
The generics of Harvoni are possible to be released after 30 July, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(5 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(5 years from now) | |
| US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
| US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(5 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
| US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
|
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(7 years from now) | |
|
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(7 years from now) | |
|
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(7 years from now) | |
|
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(7 years from now) | |
|
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(7 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(7 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
| US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
|
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(9 years from now) | |
|
US10039779 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity (ODE) | Apr 7, 2024 |
| Pediatric Exclusivity (PED) | Oct 7, 2024 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 10 October, 2014
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) inf...
Dosage: TABLET;ORAL
HARVONI family patents
81
United States
30
Japan
29
European Union
27
China
23
Korea, Republic of
19
Hong Kong
19
Taiwan
17
Spain
16
Singapore
15
Canada
14
Brazil
14
New Zealand
14
Israel
14
Portugal
14
Mexico
13
EA
12
Poland
12
Australia
12
Slovenia
11
Chile
10
Argentina
10
Hungary
9
Denmark
9
Croatia
9
Cyprus
8
South Africa
8
Lithuania
7
Uruguay
7
Peru
7
Colombia
6
RS
6
Ukraine
6
ME
6
Ecuador
5
Philippines
5
Costa Rica
4
Malaysia
4
Russia
4
Norway
4
San Marino
3
Moldova, Republic of
3
Germany
2
AP
2
Morocco
2
Netherlands
1
Turkey
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic